Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennie L Walgren

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Toxicologic Pathology|November 29, 2013
Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis modelsAmy L Usborne, Aaron T Smith, Steven K Engle, et al.
Chemical Research in Toxicology|March 29, 2008
Peptide-based in vitro assay for the detection of reactive metabolitesMichael D Mitchell, Mollisa M Elrick, Jennie L Walgren, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Toxicologic Pathology|November 29, 2013
Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis modelsAmy L Usborne, Aaron T Smith, Steven K Engle, et al.
Chemical Research in Toxicology|March 29, 2008
Peptide-based in vitro assay for the detection of reactive metabolitesMichael D Mitchell, Mollisa M Elrick, Jennie L Walgren, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 2